The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. (Q40571024)
Jump to navigation
Jump to search
scientific article published on April 2004
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. |
scientific article published on April 2004 |
Statements
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells (English)
Mien-Chie Hung
1 April 2004